Abstract

You have accessJournal of UrologyCME1 Apr 2023MP50-13 OPEN VERSUS MINIMAL INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION: A NATIONAL CANCER DATABASE ANALYSIS Harshit Garg, Mukund Bhandari, Gilda Digman, Onika Noel, Furkan Dursun, Dharam Kaushik, Deepak Pruthi, Michael Liss, Chethan Ramamurthy, and Ahmed Mansour Harshit GargHarshit Garg More articles by this author , Mukund BhandariMukund Bhandari More articles by this author , Gilda DigmanGilda Digman More articles by this author , Onika NoelOnika Noel More articles by this author , Furkan DursunFurkan Dursun More articles by this author , Dharam KaushikDharam Kaushik More articles by this author , Deepak PruthiDeepak Pruthi More articles by this author , Michael LissMichael Liss More articles by this author , Chethan RamamurthyChethan Ramamurthy More articles by this author , and Ahmed MansourAhmed Mansour More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003298.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Minimal invasive retroperitoneal lymph node dissection (RPLND), either by laparoscopic or robotic approach, has increasingly become popular. However, data comparative data on perioperative outcomes and survival outcomes is limited. In this study, we aim to compare minimal invasive -RPLND (MI-RPLND) with open (O-RPLND) using National Cancer Database. METHODS: Using the 2010-2019 National Cancer Database, patients with primary testicular germ cell tumors undergoing RPLND were identified and classified as Group A: O-RPLND and Group B: MI-RPLND. The primary outcome was overall survival (OS). Secondary outcomes included lymph nodal yield, death within 30 and 90 days of surgery, length of stay after surgery, and frequency of unplanned readmission within 30 days of surgical discharge. Inverse probability weighting (IPW) was utilized to balance the two groups. RESULTS: Overall, 3,184 patients were identified; 2971 (93.3%) patients were included in Group A and 213(6.7%) patients were included in Group B. Amongst them, 2419 (76%) had NSGCT. Factors associated with increased likelihood of MI-RPLND were treatment at academic research programs (p=0.003) and the treatment period between 2015-2019 (p<0.001). The median lymph nodal yield in O-RPLND and MI-RPLND group were similar [19 vs 22, p=0.623]. The 5-year OS was similar between the two groups [94.3% in O-RPLND vs 94.7%, in MI-RPLND p=0.77) (Figure 1a). The length of stay after surgery (p=0.623), frequency of unplanned readmission within 30 days of discharge (p=0.728), death within 30-days of surgery (p=0.74) and death within 90-days of surgery (p=0.06) were similar between the two groups. After IPW matched cohort analysis, the 5y-OS remained similar between the open and minimally invasive approach. [93.9% in O-RPLND vs 93.7% in MI-RPLND, p=0.94] (Figure 1b). CONCLUSIONS: Both O-RPLND and MI-RPLND are associated with similar OS. In terms of perioperative outcomes, both surgical approaches have similar length of hospital stay, similar rates of mortality within 30-day and 90-day of surgery, and similar rates of unplanned readmission rate within 30 days of surgical discharge. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e689 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Harshit Garg More articles by this author Mukund Bhandari More articles by this author Gilda Digman More articles by this author Onika Noel More articles by this author Furkan Dursun More articles by this author Dharam Kaushik More articles by this author Deepak Pruthi More articles by this author Michael Liss More articles by this author Chethan Ramamurthy More articles by this author Ahmed Mansour More articles by this author Expand All Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call